scPharmaceuticals Announces $100 Million Debt Financing Agreement with Oaktree
BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that the company has entered into a binding term sheet with respect to a $100 million secured debt facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”). The potential transaction is subject to the parties’ execution of definitive agreements and customary closing conditions to be stipulated therein. The definitive agreements are expected to be signed by mid-October. Cowen acted as exclusive financial advisor to scPharmaceuticals on this transaction.
Related news for (SCPH)
- 24/7 Market News Snapshot 25 August, 2025 – scPharmaceuticals Inc. Common Stock (NASDAQ:SCPH)
- MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
- MoBot’s Stock Market Highlights – 05/15/25 12:00 PM
- scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease